Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Psilocybin-assisted psychotherapy for treatment-resistant depression
ACTRN12621001097831Phase 2Completed
- Sponsor
- Swinburne University of Technology
- Start
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of psilocybin in treatment-resistant depression (TRD), sponsored by Swinburne University of Technology. Primary endpoints: Change in depression severity and Long-term change in depression severity. Started Sep 2022; status: completed.
02
Drugs
psilocybin
03
Conditions
treatment-resistant depression (TRD)
Beyond the preview
Go deeper on ACTRN12621001097831.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12621001097831.